Charles W. Locuson

1.3k total citations
44 papers, 989 citations indexed

About

Charles W. Locuson is a scholar working on Pharmacology, Oncology and Molecular Biology. According to data from OpenAlex, Charles W. Locuson has authored 44 papers receiving a total of 989 indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pharmacology, 19 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Charles W. Locuson's work include Pharmacogenetics and Drug Metabolism (25 papers), Drug Transport and Resistance Mechanisms (17 papers) and Receptor Mechanisms and Signaling (9 papers). Charles W. Locuson is often cited by papers focused on Pharmacogenetics and Drug Metabolism (25 papers), Drug Transport and Resistance Mechanisms (17 papers) and Receptor Mechanisms and Signaling (9 papers). Charles W. Locuson collaborates with scholars based in United States, France and Australia. Charles W. Locuson's co-authors include Timothy S. Tracy, Jeffrey P. Jones, Peter M. Gannett, J. Matthew Hutzler, Allan E. Rettie, Craig W. Lindsley, T. S. Tracy, Denise A. Rock, Larry C. Wienkers and J. Scott Daniels and has published in prestigious journals such as Journal of the American Chemical Society, Analytical Chemistry and Biochemistry.

In The Last Decade

Charles W. Locuson

44 papers receiving 965 citations

Peers

Charles W. Locuson
Stuart W. Paine United Kingdom
Punam Sandhu United States
Susan Cole United Kingdom
Richard Svensson Sweden
Hugues Dolgos Germany
John P. Umland United States
Kenneth S. Santone United States
Alex. M. Weir United Kingdom
Iain Martin United Kingdom
Tom Verhaeghe Belgium
Stuart W. Paine United Kingdom
Charles W. Locuson
Citations per year, relative to Charles W. Locuson Charles W. Locuson (= 1×) peers Stuart W. Paine

Countries citing papers authored by Charles W. Locuson

Since Specialization
Citations

This map shows the geographic impact of Charles W. Locuson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Charles W. Locuson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Charles W. Locuson more than expected).

Fields of papers citing papers by Charles W. Locuson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Charles W. Locuson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Charles W. Locuson. The network helps show where Charles W. Locuson may publish in the future.

Co-authorship network of co-authors of Charles W. Locuson

This figure shows the co-authorship network connecting the top 25 collaborators of Charles W. Locuson. A scholar is included among the top collaborators of Charles W. Locuson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Charles W. Locuson. Charles W. Locuson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
KuKanich, Butch, et al.. (2019). The effect of fluconazole on oral methadone in dogs. Veterinary Anaesthesia and Analgesia. 46(4). 501–509. 9 indexed citations
2.
Gogliotti, Rocco D., Changho Han, Charles W. Locuson, et al.. (2015). Progress towards small molecule menin-mixed lineage leukemia (MLL) interaction inhibitors with in vivo utility. Bioorganic & Medicinal Chemistry Letters. 25(13). 2720–2725. 11 indexed citations
3.
Lepesheva, Galina I., Tatiana Y. Hargrove, Girish Rachakonda, et al.. (2015). VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis. The Journal of Infectious Diseases. 212(9). 1439–1448. 51 indexed citations
4.
Blobaum, Anna L., Frank W. Byers, Thomas M. Bridges, et al.. (2015). A Screen of Approved Drugs Identifies the Androgen Receptor Antagonist Flutamide and Its Pharmacologically Active Metabolite 2-Hydroxy-Flutamide as Heterotropic Activators of Cytochrome P450 3A In Vitro and In Vivo. Drug Metabolism and Disposition. 43(11). 1718–1726. 8 indexed citations
5.
Engers, Darren W., E Ennis, Jane Wright, et al.. (2015). Synthesis and structure–activity relationships of a series of 4-methoxy-3-(piperidin-4-yl)oxy benzamides as novel inhibitors of the presynaptic choline transporter. Bioorganic & Medicinal Chemistry Letters. 25(8). 1757–1760. 4 indexed citations
6.
Duvernay, Matthew T., M. Schulte, Kellie D. Nance, et al.. (2014). Substituted indoles as selective protease activated receptor 4 (PAR-4) antagonists: Discovery and SAR of ML354. Bioorganic & Medicinal Chemistry Letters. 24(19). 4708–4713. 29 indexed citations
7.
O’Reilly, Matthew C., Thomas H. Oguin, Sarah Scott, et al.. (2014). Discovery of a Highly Selective PLD2 Inhibitor (ML395): A New Probe with Improved Physiochemical Properties and Broad‐Spectrum Antiviral Activity against Influenza Strains. ChemMedChem. 9(12). 2633–2637. 15 indexed citations
8.
Sampson, Kathleen E., et al.. (2011). Pharmacokinetic Interaction of the Antiparasitic Agents Ivermectin and Spinosad in Dogs. Drug Metabolism and Disposition. 39(5). 789–795. 42 indexed citations
9.
Yancey, Mark, Dawn A. Merritt, Julie White, Susan A. Marsh, & Charles W. Locuson. (2010). Distribution, metabolism, and excretion of toceranib phosphate (Palladia™, SU11654), a novel tyrosine kinase inhibitor, in dogs. Journal of Veterinary Pharmacology and Therapeutics. 33(2). 154–161. 23 indexed citations
10.
Subramanian, Murali, et al.. (2009). CYP2D6-CYP2C9 Protein-Protein Interactions and Isoform-Selective Effects on Substrate Binding and Catalysis. Drug Metabolism and Disposition. 37(8). 1682–1689. 41 indexed citations
11.
Zaya, Matthew J., et al.. (2008). In Vitro Drug-Drug Interaction Screens for Canine Veterinary Medicines: Evaluation of Cytochrome P450 Reversible Inhibition. Drug Metabolism and Disposition. 36(8). 1512–1518. 27 indexed citations
12.
Locuson, Charles W., J. Matthew Hutzler, & Timothy S. Tracy. (2007). Visible Spectra of Type II Cytochrome P450-Drug Complexes: Evidence that “Incomplete” Heme Coordination Is Common. Drug Metabolism and Disposition. 35(4). 614–622. 63 indexed citations
13.
Locuson, Charles W. & T. S. Tracy. (2007). Comparative modelling of the human UDP-glucuronosyltransferases: Insights into structure and mechanism. Xenobiotica. 37(2). 155–168. 33 indexed citations
14.
Locuson, Charles W., et al.. (2007). Polymorphic Variants of CYP2C9: Mechanisms Involved in Reduced Catalytic Activity. Molecular Pharmacology. 72(5). 1280–1288. 49 indexed citations
15.
Locuson, Charles W. & Timothy S. Tracy. (2006). Identification of Binding Sites of Non-I-Helix Water Molecules in Mammalian Cytochromes P450. Drug Metabolism and Disposition. 34(12). 1954–1957. 6 indexed citations
16.
Locuson, Charles W., Peter M. Gannett, & Timothy S. Tracy. (2006). Heteroactivator effects on the coupling and spin state equilibrium of CYP2C9. Archives of Biochemistry and Biophysics. 449(1-2). 115–129. 32 indexed citations
17.
Hutzler, J. Matthew, Roger J. Melton, Jeanne M. Rumsey, et al.. (2006). Inhibition of Cytochrome P450 3A4 by a Pyrimidineimidazole:  Evidence for Complex Heme Interactions. Chemical Research in Toxicology. 19(12). 1650–1659. 28 indexed citations
18.
Locuson, Charles W. & Jan L. Wahlstrom. (2005). THREE-DIMENSIONAL QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP ANALYSIS OF CYTOCHROMES P450: EFFECT OF INCORPORATING HIGHER-AFFINITY LIGANDS AND POTENTIAL NEW APPLICATIONS. Drug Metabolism and Disposition. 33(7). 873–878. 15 indexed citations
19.
Hummel, Matthew A., Charles W. Locuson, Peter M. Gannett, et al.. (2005). CYP2C9 Genotype-Dependent Effects on in Vitro Drug-Drug Interactions: Switching of Benzbromarone Effect from Inhibition to Activation in the CYP2C9.3 Variant. Molecular Pharmacology. 68(3). 644–651. 39 indexed citations
20.
Locuson, Charles W., Jan L. Wahlstrom, Denise A. Rock, Dan A. Rock, & Jeffrey P. Jones. (2003). A NEW CLASS OF CYP2C9 INHIBITORS: PROBING 2C9 SPECIFICITY WITH HIGH-AFFINITY BENZBROMARONE DERIVATIVES. Drug Metabolism and Disposition. 31(7). 967–971. 30 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Stuart W. Paine Breakdown of academic impact, for papers by Punam Sandhu Breakdown of academic impact, for papers by Susan Cole Breakdown of academic impact, for papers by Richard Svensson Breakdown of academic impact, for papers by Hugues Dolgos Breakdown of academic impact, for papers by John P. Umland Breakdown of academic impact, for papers by Kenneth S. Santone Breakdown of academic impact, for papers by Alex. M. Weir Breakdown of academic impact, for papers by Iain Martin Breakdown of academic impact, for papers by Tom Verhaeghe
Rankless by CCL
2026